Dinnon KH 3rd, Leist SR, Schäfer A, Edwards CE, Martinez DR, Montgomery SA, West A, Yount BL Jr, Hou YJ, Adams LE, Gully KL, Brown AJ, Huang E, Bryant MD, Choong IC, Glenn JS, Gralinski LE, Sheahan TP, Baric RS., A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures, Nature. 2020 Oct;586(7830):560-566. doi: 10.1038/s41586-020-2708-8. Epub 2020 Aug 27.
Arruabarrena-Aristorena A, Maag JLV, Kittane S, Cai Y, Karthaus WR, Ladewig E, Park J, Kannan S, Ferrando L, Cocco E, Ho SY, Tan DS, Sallaku M, Wu F, Acevedo B, Selenica P, Ross DS, Witkin M, Sawyers CL, Reis-Filho JS, Verma CS, Jauch R, Koche R, Baselga J, Razavi P, Toska E, Scaltriti M., FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer, Cancer Cell. 2020 Oct 12;38(4):534-550.e9. doi: 10.1016/j.ccell.2020.08.003. Epub 2020 Sep 3.
Dinami R, Pompili L, Petti E, Porru M, D'Angelo C, Di Vito S, Rizzo A, Campani V, De Rosa G, Bruna A, Serra V, Mano M, Giacca M, Leonetti C, Ciliberto G, Tarsounas M, Stoppacciaro A, Schoeftner S, Biroccio A., MiR-182-3p targets TRF2 and impairs tumor growth of triple-negative breast cancer., EMBO Mol Med. 2023 Jan 11;15(1):e16033. doi: 10.15252/emmm.202216033. Epub 2022 Nov 25.
Frees, S., Bidnur, S., Metcalfe, M., Raven, P., Chavez-Munoz, C., Moskalev, I., . . . So, A. (2016), Effect of contrast media on urinary cytopathology specimens., Canadian Urological Association Journal = Journal De l'Association Des Urologues Du Canada, 10(7-8), 228-233. doi:10.5489/cuaj.3874 [doi]
Houweling M, Abdul UK, Brahm C, Lagerweij T, Heukelom S, Koken PW, Honeywell R, Wedekind LE, Peters GJ, Verheul H, Sminia P, Noske D, Wurdinger T, Westerman BA., Radio-sensitizing effect of MEK inhibition in glioblastoma in vitro and in vivo, J Cancer Res Clin Oncol. 2022 Dec 1. doi: 10.1007/s00432-022-04483-3. Online ahead of print.
Basu, Sankha S; Regan, Michael S; Randall, Elizabeth C; Abdelmoula, Walid M; Clark, Amanda R; Gimenez-Cassina Lopez, BegoĂąa; Cornett, Dale S; Haase, Andreas; Santagata, Sandro; Agar, Nathalie Y R;, Rapid MALDI mass spectrometry imaging for surgical pathology., NPJ precision oncology Vol.3, 2019
Debing, Y., Mishra, N., Verbeken, E., Ramaekers, K., Dallmeier, K., & Neyts, J. (2016)., A rat model for hepatitis E virus., Disease Models & Mechanisms, 9(10), 1203-1210. doi:dmm.024406 [pii]
Yang, Hailing; Shu, Zhang; Jiang, Yongying; Mao, Weiqun; Pang, Lan; Redwood, Abena; Jeter-Jones, Sabrina L; Jennings, Nicholas B; Ornelas, Argentina; Zhou, Jinhua; Rodriguez-Aguayo, Cristian; Bartholomeusz, Geoffrey; Iles, LaKesla R; Zacharias, Niki M; Millward, Steven W; Lopez-Berestein, Gabriel; Le, Xiao-Feng; Ahmed, Ahmed A; Piwnica-Worms, Helen; Sood, Anil K; Bast, Robert C; Lu, Zhen, 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers, Clinical cancer research : an official journal of the American Association for Cancer Research Vol.25, 2019
Ziegler, J., Bastian, A., Lerner, M., Bailey-Downs, L., Saunders, D., Smith, N., . . . Towner, R. A. (2017)., AG488 as a therapy against gliomas., Oncotarget, 8(42), 71833-71844. doi:10.18632/oncotarget.18284 [doi]
Gomes AP, Ilter D, Low V, Endress JE, Fernández-García J, Rosenzweig A, Schild T, Broekaert D, Ahmed A, Planque M, Elia I, Han J, Kinzig C, Mullarky E, Mutvei AP, Asara J, de Cabo R, Cantley LC, Dephoure N, Fendt SM, Blenis J., Age-induced accumulation of methylmalonic acid promotes tumour progression, Nature. 2020 Sep;585(7824):283-287. doi: 10.1038/s41586-020-2630-0. Epub 2020 Aug 19.
Sun Y, Meyers BA, Czako B, Leonard P, Mseeh F, Harris AL, Wu Q, Johnson S, Parker CA, Cross JB, Di Francesco ME, Bivona BJ, Bristow CA, Burke JP, Carrillo CC, Carroll CL, Chang Q, Feng N, Gao G, Gera S, Giuliani V, Huang JK, Jiang Y, Kang Z, Kovacs JJ, Liu CY, Lopez AM, Ma X, Mandal PK, McAfoos T, Miller MA, Mullinax RA, Peoples M, Ramamoorthy V, Seth S, Spencer ND, Suzuki E, Williams CC, Yu SS, Zuniga AM, Draetta GF, Marszalek JR, Heffernan TP, Kohl NE, Jones P., Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib, Cancer Res. 2020 Nov 1;80(21):4840-4853. doi: 10.1158/0008-5472.CAN-20-1634. Epub 2020 Sep 14.
Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, Laguer J, Medwid J, Vanderpool D, Lifset E, Trinh D, Hoffman N, Wang X, David Lawson J, Gunn RJ, Smith CR, Thomas NC, Martinson M, Bergstrom A, Sullivan F, Bouhana K, Winski S, He L, Fernandez-Banet J, Pavlicek A, Haling JR, Rahbaek L, Marx MA, Olson P, Christensen JG., Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor, Nat Med. 2022 Oct;28(10):2171-2182. doi: 10.1038/s41591-022-02007-7. Epub 2022 Oct 10.
Su W, Mukherjee R, Yaeger R, Son J, Xu J, Na N, Merna Timaul N, Hechtman J, Paroder V, Lin M, Mattar M, Qiu J, Chang Q, Zhao H, Zhang J, Little M, Adachi Y, Han SW, Taylor BS, Ebi H, Abdel-Wahab O, de Stanchina E, Rudin CM, Jänne PA, McCormick F, Yao Z, Rosen N., ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1, Mol Cell. 2022 Jul 7;82(13):2443-2457.e7. doi: 10.1016/j.molcel.2022.04.034. Epub 2022 May 24.
Fok, Jacqueline H L; Ramos-Montoya, Antonio; Vazquez-Chantada, Mercedes; Wijnhoven, Paul W G; Follia, Valeria; James, Neil; Farrington, Paul M; Karmokar, Ankur; Willis, Sophie E; Cairns, Jonathan; Nikkilä, Jenni; Beattie, David; Lamont, Gillian M; Finlay, M Raymond V; Wilson, Joanne; Smith, Aaron; OConnor, Lenka Oplustil; Ling, Stephanie; Fawell, Stephen E; OConnor, Mark J; Hollingsworth, Simon J; Dean, Emma; Goldberg, Frederick W; Davies, Barry R; Cadogan, Elaine B;, AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity., Nature communications Vol.10, 2019
Bolaender A, Zatorska D, He H, Joshi S, Sharma S, Digwal CS, Patel HJ, Sun W, Imber BS, Ochiana SO, Patel MR, Shrestha L, Shah SK, Wang S, Karimov R, Tao H, Patel PD, Martin AR, Yan P, Panchal P, Almodovar J, Corben A, Rimner A, Ginsberg SD, Lyashchenko S, Burnazi E, Ku A, Kalidindi T, Lee SG, Grkovski M, Beattie BJ, Zanzonico P, Lewis JS, Larson S, Rodina A, Pillarsetty N, Tabar V, Dunphy MP, Taldone T, Shimizu F, Chiosis G., Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system, Nat Commun. 2021 Aug 3;12(1):4669. doi: 10.1038/s41467-021-24821-2.
Nordmaj MA, Roberts ME, Sachse ES, Dagil R, Andersen AP, Skeltved N, Grunddal KV, Erdoğan SM, Choudhary S, Gustsavsson T, Ørum-Madsen MS, Moskalev I, Tian W, Yang Z, Clausen TM, Theander TG, Daugaard M, Nielsen MA, Salanti A., Development of a bispecific immune engager using a recombinant malaria protein, Cell Death Dis. 2021 Apr 6;12(4):353. doi: 10.1038/s41419-021-03611-0.
Bhagwat SV, McMillen WT, Cai S, Zhao B, Whitesell M, Shen W, Kindler L, Flack RS, Wu W, Anderson B, Zhai Y, Yuan XJ, Pogue M, Van Horn RD, Rao X, McCann D, Dropsey AJ, Manro J, Walgren J, Yuen E, Rodriguez MJ, Plowman GD, Tiu RV, Joseph S, Peng SB., ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine, Mol Cancer Ther. 2020 Feb;19(2):325-336. doi: 10.1158/1535-7163.MCT-19-0183. Epub 2019 Nov 19.
Maaland, Astri Fjelde; Heyerdahl, Helen; OShea, Adam; Eiriksdottir, Bergthora; Pascal, VĂŠronique; Andersen, Jan Terje; Kolstad, Arne; Dahle, Jostein;, European journal of nuclear medicine and molecular imaging Vol.46, 2019, European journal of nuclear medicine and molecular imaging Vol.46, 2019
Sperger JM, Helzer KT, Stahlfeld CN, Jiang D, Singh A, Kaufmann KR, Niles DJ, Heninger E, Rydzewski NR, Wang L, Wang L, Yang R, Ren Y, Engle JW, Huang P, Kyriakopoulos CE, Slovin SF, Soule HR, Zhao SG, Kohli M, Tagawa ST, Cai W, et al., Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer., Clin Cancer Res. 2023 Jun 13;29(12):2324-2335. doi: 10.1158/1078-0432.CCR-22-1305.
Sánchez-Guixé M, Hierro C, Jiménez J, Viaplana C, Villacampa G, Monelli E, Brasó-Maristany F, Ogbah Z, Parés M, Guzmán M, Grueso J, Rodríguez O, Oliveira M, Azaro A, Garralda E, Tabernero J, Casanovas O, Scaltriti M, Prat A, Dienstmann R, Nuciforo P, Saura C, Graupera M, Vivancos A, Rodon J, Serra V., High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer, Clin Cancer Res. 2021 Sep 30. doi: 10.1158/1078-0432.CCR-21-1810. Online ahead of print.
Sánchez-Guixé M, Hierro C, Jiménez J, Viaplana C, Villacampa G, Monelli E, Brasó-Maristany F, Ogbah Z, Parés M, Guzmán M, Grueso J, Rodríguez O, Oliveira M, Azaro A, Garralda E, Tabernero J, Casanovas O, Scaltriti M, Prat A, Dienstmann R, Nuciforo P, Saura C, Graupera M, Vivancos A, Rodon J, Serra V., High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer, Clin Cancer Res. 2022 Jan 1;28(1):137-149. doi: 10.1158/1078-0432.CCR-21-1810. Epub 2021 Sep 30.
Serra V, Wang AT, Castroviejo-Bermejo M, Polanska UM, Palafox M, Herencia-Ropero A, Jones GN, Lai Z, Armenia J, Michopoulos F, Llop-Guevara A, Brough R, Gulati A, Pettitt SJ, Bulusu KC, Nikkilä J, Wilson Z, Hughes A, Wijnhoven PWG, Ahmed A, Bruna A, Gris-Oliver A, Guzman M, Rodríguez O, Grueso J, Arribas J, Cortés J, Saura C, Lau A, Critchlow S, Dougherty B, Caldas C, Mills GB, Barrett JC, Forment JV, Cadogan E, Lord CJ, Cruz C, Balmaña J, O'Connor MJ., Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance, Clin Cancer Res. 2022 Oct 14;28(20):4536-4550. doi: 10.1158/1078-0432.CCR-22-0568.
Fell JB, Fischer JP, Baer BR, Blake JF, Bouhana K, Briere DM, Brown KD, Burgess LE, Burns AC, Burkard MR, Chiang H, Chicarelli MJ, Cook AW, Gaudino JJ, Hallin J, Hanson L, Hartley DP, Hicken EJ, Hingorani GP, Hinklin RJ, Mejia MJ, Olson P, Otten JN, Rhodes SP, Rodriguez ME, Savechenkov P, Smith DJ, Sudhakar N, Sullivan FX, Tang TP, Vigers GP, Wollenberg L, Christensen JG, Marx MA., Identification of the Clinical Development Candidate MRTX849, a Covalent KRAS(G12C) Inhibitor for the Treatment of Cancer, J Med Chem. 2020 Jul 9;63(13):6679-6693. doi: 10.1021/acs.jmedchem.9b02052. Epub 2020 Apr 6.
Rybczynska, A. A., de Bruyn, M., Ramakrishnan, N. K., de Jong, J. R., Elsinga, P. H., Helfrich, W., . . . van Waarde, A. (2013)., In vivo responses of human A375M melanoma to a sigma ligand: 18F-FDG PET imaging., Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 54(9), 1613-1620. doi:10.2967/jnumed.113.122655 [doi]
Gómez-Aleza C, Nguyen B, Yoldi G, Ciscar M, Barranco A, Hernández-Jiménez E, Maetens M, Salgado R, Zafeiroglou M, Pellegrini P, Venet D, Garaud S, Trinidad EM, Benítez S, Vuylsteke P, Polastro L, Wildiers H, Simon P, Lindeman G, Larsimont D, Van den Eynden G, Velghe C, Rothé F, Willard-Gallo K, Michiels S, Muñoz P, Walzer T, Planelles L, Penninger J, Azim HA Jr, Loi S, Piccart M, Sotiriou C, González-Suárez E., Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells, Nat Commun. 2020 Dec 10;11(1):6335. doi: 10.1038/s41467-020-20138-8.
Bouguenina H, Nicolaou S, Le Bihan YV, Bowling EA, Calderon C, Caldwell JJ, Harrington B, Hayes A, McAndrew PC, Mitsopoulos C, Sialana FJ, Scarpino A, Stubbs M, Thapaliya A, Tyagi S, Wang HZ, Wood F, Burke R, Raynaud F, Choudhary J, van Montfort RLM, Sadok A, et al., iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells., iScience. 2023 Jun 7;26(7):107059. doi: 10.1016/j.isci.2023.107059. eCollection 2023 Jul 21.
Dwivedi SKD, Shameer K, Dey A, Mustafi SB, Xiong X, Bhattacharya U, Neizer-Ashun F, Rao G, Wang Y, Ivan C, Yang D, Dudley JT, Xu C, Wren JD, Mukherjee P, Bhattacharya R., KRCC1: A potential therapeutic target in ovarian cancer, FASEB J. 2020 Feb;34(2):2287-2300. doi: 10.1096/fj.201902259R. Epub 2019 Dec 23.
Pascual-Pasto G, Resa-Pares C, Castillo-Ecija H, Aschero R, Baulenas-Farres M, Vila-Ubach M, Burgueño V, Balaguer-Lluna L, Cuadrado-Vilanova M, Olaciregui NG, Martinez-Velasco N, Perez-Jaume S, de Alava E, Tirado OM, Lavarino C, Mora J, Carcaboso AM., Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma, Biochem Pharmacol. 2023 Jan 2;208:115408. doi: 10.1016/j.bcp.2022.115408. Online ahead of print.
Pascual-Pasto G, Resa-Pares C, Castillo-Ecija H, Aschero R, Baulenas-Farres M, Vila-Ubach M, Burgueño V, Balaguer-Lluna L, Cuadrado-Vilanova M, Olaciregui NG, Martinez-Velasco N, Perez-Jaume S, de Alava E, Tirado OM, Lavarino C, Mora J, Carcaboso AM., Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma., Biochem Pharmacol. 2023 Feb;208:115408. doi: 10.1016/j.bcp.2022.115408. Epub 2023 Jan 2.
Kalev P, Hyer ML, Gross S, Konteatis Z, Chen CC, Fletcher M, Lein M, Aguado-Fraile E, Frank V, Barnett A, Mandley E, Goldford J, Chen Y, Sellers K, Hayes S, Lizotte K, Quang P, Tuncay Y, Clasquin M, Peters R, Weier J, Simone E, Murtie J, Liu W, Nagaraja R, Dang L, Sui Z, Biller SA, Travins J, Marks KM, Marjon K., MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage, Cancer Cell. 2021 Feb 8;39(2):209-224.e11. doi: 10.1016/j.ccell.2020.12.010. Epub 2021 Jan 14.
Gonzalvez F, Vincent S, Baker TE, Gould AE, Li S, Wardwell SD, Nadworny S, Ning Y, Zhang S, Huang WS, Hu Y, Li F, Greenfield MT, Zech SG, Das B, Narasimhan NI, Clackson T, Dalgarno D, Shakespeare WC, Fitzgerald M, Chouitar J, Griffin RJ, Liu S, Wong KK, Zhu X, Rivera VM., Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer, Cancer Discov. 2021 Jul;11(7):1672-1687. doi: 10.1158/2159-8290.CD-20-1683. Epub 2021 Feb 25.
Yan P, Patel HJ, Sharma S, Corben A, Wang T, Panchal P, Yang C, Sun W, Araujo TL, Rodina A, Joshi S, Robzyk K, Gandu S, White JR, de Stanchina E, Modi S, Janjigian YY, Hill EG, Liu B, Erdjument-Bromage H, Neubert TA, Que NLS, Li Z, Gewirth DT, Taldone T, Chiosis G., Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone, Cell Rep. 2020 Jun 30;31(13):107840. doi: 10.1016/j.celrep.2020.107840.
Yan P, Patel HJ, Sharma S, Corben A, Wang T, Panchal P, Yang C, Sun W, Araujo TL, Rodina A, Joshi S, Robzyk K, Gandu S, White JR, de Stanchina E, Modi S, Janjigian YY, Hill EG, Liu B, Erdjument-Bromage H, Neubert TA, Que NLS, Li Z, Gewirth DT, Taldone T, Chiosis G., Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone, Cell Rep. 2020 Jun 30;31(13):107840. doi: 10.1016/j.celrep.2020.107840.
Morcillo, M. A., Garcia de Lucas, A., Oteo, M., Romero, E., Magro, N., Ibanez, M., . . . Martinez-Torrecuadrada, J. (2018)., MT1-MMP as a PET imaging biomarker for pancreas cancer management., Contrast Media & Molecular Imaging, 2018, 8382148. doi:10.1155/2018/8382148 [doi]
Zheng ZY, Anurag M, Lei JT, Cao J, Singh P, Peng J, Kennedy H, Nguyen NC, Chen Y, Lavere P, Li J, Du XH, Cakar B, Song W, Kim BJ, Shi J, Seker S, Chan DW, Zhao GQ, Chen X, Banks KC, Lanman RB, Shafaee MN, Zhang XH, Vasaikar S, Zhang B, Hilsenbeck SG, Li W, Foulds CE, Ellis MJ, Chang EC., Neurofibromin Is an Estrogen Receptor-α Transcriptional Co-repressor in Breast Cancer, Cancer Cell. 2020 Mar 16;37(3):387-402.e7. doi: 10.1016/j.ccell.2020.02.003. Epub 2020 Mar 5.
Bousquet Mur E, Bernardo S, Papon L, Mancini M, Fabbrizio E, Goussard M, Ferrer I, Giry A, Quantin X, Pujol JL, Calvayrac O, Moll HP, Glasson Y, Pirot N, Turtoi A, CaĂąamero M, Wong KK, Yarden Y, Casanova E, Soria JC, Colinge J, Siebel CW, Mazieres J, Favre G, Paz-Ares L, Maraver A., Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma, J Clin Invest. 2020 Feb 3;130(2):612-624. doi: 10.1172/JCI126896.
Vasciaveo A, Arriaga JM, de Almeida FN, Zou M, Douglass EF, Picech F, Shibata M, Rodriguez-Calero A, de Brot S, Mitrofanova A, Chua CW, Karan C, Realubit R, Pampou S, Kim JY, Afari SN, Mukhammadov T, Zanella L, Corey E, Alvarez MJ, Rubin MA, Shen MM, et al., OncoLoop: A Network-Based Precision Cancer Medicine Framework., Cancer Discov. 2023 Feb 6;13(2):386-409. doi: 10.1158/2159-8290.CD-22-0342.
Staniszewska AD, Armenia J, King M, Michaloglou C, Reddy A, Singh M, San Martin M, Prickett L, Wilson Z, Proia T, Russell D, Thomas M, Delpuech O, O'Connor MJ, Leo E, Angell H, Valge-Archer V., PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors, Oncoimmunology. 2022 Jun 18;11(1):2083755. doi: 10.1080/2162402X.2022.2083755. eCollection 2022.
Gozgit JM, Vasbinder MM, Abo RP, Kunii K, Kuplast-Barr KG, Gui B, Lu AZ, Molina JR, Minissale E, Swinger KK, Wigle TJ, Blackwell DJ, Majer CR, Ren Y, Niepel M, Varsamis ZA, Nayak SP, Bamberg E, Mo JR, Church WD, Mady ASA, Song J, Utley L, Rao PE, Mitchison TJ, Kuntz KW, Richon VM, Keilhack H., PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity, Cancer Cell. 2021 Sep 13;39(9):1214-1226.e10. doi: 10.1016/j.ccell.2021.06.018. Epub 2021 Jul 22.
Kamiyama, H., Rauenzahn, S., Shim, J. S., Karikari, C. A., Feldmann, G., Hua, L., . . . Eshleman, J. R. (2013)., Personalized chemotherapy profiling using cancer cell lines from selectable mice., Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 19(5), 1139-1146. doi:10.1158/1078-0432.CCR-12-2127 [doi]
Bähr-Mahmud, H., Ellinghaus, U., Stadler, C. R., Fischer, L., Lindemann, C., Chaturvedi, A., Diekmann, J., Wöll, S., Biermann, I., Hebich, B., Scharf, C., Siefke, M., Roth, A. S., Rao, M., Brettschneider, K., Ewen, E. M., Şahin, U., & Türeci, Ö., Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody., Oncoimmunology. 2023 Oct 16;12(1):2255041. doi: 10.1080/2162402X.2023.2255041. eCollection 2023.
Staniszewska AD, Pilger D, Gill SJ, Jamal K, Bohin N, Guzzetti S, Gordon J, Hamm G, Mundin G, Illuzzi G, Pike A, McWilliams L, Maglennon G, Rose J, Hawthorne G, Cortes Gonzalez M, Halldin C, Johnström P, Schou M, Critchlow SE, Fawell S, Johannes JW, et al., Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1., Clin Cancer Res. 2023 Nov 15. doi: 10.1158/1078-0432.CCR-23-2094. [Epub ahead of print]
Scribner JA, Brown JG, Son T, Chiechi M, Li P, Sharma S, Li H, De Costa A, Li Y, Chen Y, Easton A, Yee-Toy NC, Chen FZ, Gorlatov S, Barat B, Huang L, Wolff CR, Hooley J, Hotaling TE, Gaynutdinov T, Ciccarone V, Tamura J, Koenig S, Moore PA, Bonvini E, Loo D., Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer, Mol Cancer Ther. 2020 Sep 23:molcanther.0116.2020. doi: 10.1158/1535-7163.MCT-20-0116. Online ahead of print.
Scribner JA, Hicks SW, Sinkevicius KW, Yoder NC, Diedrich G, Brown JG, Lucas J, Fuller ME, Son T, Dastur A, Hooley J, Espelin C, Themeles M, Chen FZ, Li Y, Chiechi M, Lee J, Barat B, Widjaja L, Gorlatov S, Tamura J, Ciccarone V, Ab O, McEachem KA, Koenig S, Westin EH, Moore PA, Chittenden T, Gregory RJ, Bonvini E, Loo D., Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors, Mol Cancer Ther. 2022 Jul 5;21(7):1047-1059. doi: 10.1158/1535-7163.MCT-21-0915.
Houweling M, Abdul UK, Brahm C, Lagerweij T, Heukelom S, Koken PW, Honeywell R, Wedekind LE, Peters GJ, Verheul H, Sminia P, Noske D, Wurdinger T, Westerman BA., Radio-sensitizing effect of MEK inhibition in glioblastoma in vitro and in vivo., J Cancer Res Clin Oncol. 2023 Jan;149(1):297-305. doi: 10.1007/s00432-022-04483-3. Epub 2022 Dec 1.
Smith, Bryan D; Kaufman, Michael D; Lu, Wei-Ping; Gupta, Anu; Leary, Cynthia B; Wise, Scott C; Rutkoski, Thomas J; Ahn, Yu Mi; Al-Ani, Gada; Bulfer, Stacie L; Caldwell, Timothy M; Chun, Lawrence; Ensinger, Carol L; Hood, Molly M; McKinley, Arin; Patt, William C; Ruiz-Soto, Rodrigo; Su, Ying; Telikepalli, Hanumaiah; Town, Ajia; Turner, Benjamin A; Vogeti, Lakshminarayana; Vogeti, Subha; Yates, Karen; Janku, Filip; Abdul Razak, Albiruni Ryan; Rosen, Oliver; Heinrich, Michael C; Flynn, Daniel L;, Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants., Cancer cell Vol.35, 2019
Sen, M., Joyce, S., Panahandeh, M., Li, C., Thomas, S. M., Maxwell, J., . . . Grandis, J. R. (2012), Targeting Stat3 abrogates EGFR inhibitor resistance in cancer., Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 18(18), 4986-4996. doi:10.1158/1078-0432.CCR-12-0792 [doi]
Capone E, Lamolinara A, Pastorino F, Gentile R, Ponziani S, Di Vittorio G, D'Agostino D, Bibbò S, Rossi C, Piccolo E, Iacobelli V, Lattanzio R, Panella V, Sallese M, De Laurenzi V, Giansanti F, Sala A, Iezzi M, Ponzoni M, Ippoliti R, Iacobelli S, Sala G., Targeting Vesicular LGALS3BP by an Antibody-Drug Conjugate as Novel Therapeutic Strategy for Neuroblastoma, Cancers (Basel). 2020 Oct 15;12(10):2989. doi: 10.3390/cancers12102989.
Bado IL, Zhang W, Hu J, Xu Z, Wang H, Sarkar P, Li L, Wan YW, Liu J, Wu W, Lo HC, Kim IS, Singh S, Janghorban M, Muscarella AM, Goldstein A, Singh P, Jeong HH, Liu C, Schiff R, Huang S, Ellis MJ, Gaber MW, Gugala Z, Liu Z, Zhang XH., The bone microenvironment increases phenotypic plasticity of ER(+) breast cancer cells, Dev Cell. 2021 Apr 19;56(8):1100-1117.e9. doi: 10.1016/j.devcel.2021.03.008.
Zhang W, Bado IL, Hu J, Wan YW, Wu L, Wang H, Gao Y, Jeong HH, Xu Z, Hao X, Lege BM, Al-Ouran R, Li L, Li J, Yu L, Singh S, Lo HC, Niu M, Liu J, Jiang W, Li Y, Wong STC, Cheng C, Liu Z, Zhang XH., The bone microenvironment invigorates metastatic seeds for further dissemination, Cell. 2021 Apr 29;184(9):2471-2486.e20. doi: 10.1016/j.cell.2021.03.011. Epub 2021 Apr 19.
Soukupová J, Bordoni C, Turnham DJ, Yang WW, Seaton G, Gruca A, French R, Lee KY, Varnava A, Piggott L, Clarkson RWE, Westwell AD, Brancale A., The Discovery of a Novel Antimetastatic Bcl3 Inhibitor, Mol Cancer Ther. 2021 May;20(5):775-786. doi: 10.1158/1535-7163.MCT-20-0283. Epub 2021 Mar 1.